TY - JOUR T1 - Myasthenia gravis: Frequently asked questions JF - Cleveland Clinic Journal of Medicine JO - Cleve Clin J Med SP - 103 LP - 113 DO - 10.3949/ccjm.90a.22017 VL - 90 IS - 2 AU - John A. Morren AU - Yuebing Li Y1 - 2023/02/01 UR - http://www.ccjm.org/content/90/2/103.abstract N2 - Myasthenia gravis is a disorder of neuromuscular junction transmission, the result of antibodies against the post-synaptic aspect of the neuromuscular junction. Its clinical hallmark is fatigable weakness of skeletal muscles, which tends to vary in location and severity among patients. It is treated with pyridostigmine, immunotherapy, and thymectomy. Treatment is often individualized according to disease severity, antibody status, comorbidities, and other factors. This review uses a question-and-answer format to provide up-to-date, high-yield, clinically relevant information on myasthenia gravis. ER -